# V1 Empirics Check — openai/gpt-5.4 (Variant A)

**Model:** openai/gpt-5.4
**Variant:** A
**Date:** 2026-04-07T22:49:33.511397

---

## 1. **Idea Fidelity**

The paper only partially pursues the original idea in the manifest, and in ways that materially weaken the design.

First, the manifest’s core contribution was a **county-year design using lung cancer mortality** from CDC WONDER, with identification coming from a **geology × policy interaction while absorbing state-year shocks**:  
\[
Y_{cst}=\beta(\text{PostRRNC}_{st}\times \text{HighGRP}_c)+\text{County FE}+\text{State-Year FE}.
\]
That is an appealing design because it compares high- and low-geology counties **within the same state-year**, thereby netting out statewide confounders and aligning treatment heterogeneity with the biological mechanism.

The paper instead uses a **state-year panel**, **all-cancer mortality** rather than lung cancer, and state-level fixed effects plus year fixed effects. It aggregates geology to the state level and estimates a state-level interaction. This is a major departure from the manifest. In particular, moving from county-year with state-year FE to state-year collapses away the most credible source of quasi-experimental variation. The resulting design is much closer to a conventional staggered-adoption DiD across states, where adoption is likely related to radon risk, regulatory capacity, health policy preferences, and other time-varying state characteristics.

Second, the manifest emphasized that some RRNC policies apply only to **EPA Zone 1 counties**. The paper acknowledges this institutional feature but does not implement treatment at the relevant geographic level. Treating Washington and Michigan as state-level adoptions is inconsistent with the policy itself and introduces nontrivial measurement error.

Third, the manifest proposed **secondary outcomes** closer to the policy’s first stage—radon testing, building permits, housing market outcomes. The paper mentions the importance of a first stage in the discussion, but does not estimate one. Given the latency problem, those intermediate outcomes are central, not ancillary.

So the paper captures the broad question—whether RRNC codes reduce cancer mortality—but does not implement the original identification strategy, and in doing so substantially reduces credibility and relevance.

## 2. **Summary**

This paper studies whether state adoption of radon-resistant new construction codes reduced cancer mortality in the United States. Using a state-year staggered-adoption DiD from 1999–2017, interacted with a state-level measure of geological radon potential, the paper finds no detectable effects on all-cancer mortality and interprets the null as consistent with long disease latency and slow housing-stock turnover.

The topic is important and the null result could be informative. However, the current empirical design is not well matched to the research question, and the main estimates are too attenuated and too weakly identified to support strong conclusions about the health effects of RRNC policy.

## 3. **Essential Points**

1. **The identification strategy is currently not credible enough for a causal claim.**  
   The paper’s state-level DiD does not exploit the strongest available variation and leaves serious concerns about endogenous policy adoption. States adopting RRNC codes are plausibly different in health policy orientation, smoking control, building regulation, income growth, and environmental risk salience. State and year fixed effects do not address state-specific evolving trends. The original county-level geology × policy design with **county FE and state-year FE** would be much more convincing because it compares high- and low-radon-potential counties within the same state-year. As written, the paper should either implement that design or significantly scale back its causal language.

2. **The outcome and unit of analysis are badly mismatched to the mechanism.**  
   The paper uses all-cancer mortality at the state-year level even though radon should affect lung cancer specifically, and only through new construction. This creates massive attenuation. The paper is upfront about this, but acknowledgement is not a substitute for measurement. A design that cannot plausibly detect the object of interest should not be the paper’s main analysis. At minimum, the authors need to move to lung-cancer-specific outcomes and, ideally, finer geography.

3. **The paper needs a first-stage / mechanism analysis; otherwise the null is uninterpretable.**  
   Without evidence that RRNC adoption actually changed indoor radon exposure, construction practices, testing, or code-compliant housing shares, the reader cannot distinguish between “the policy had no health effect yet” and “the policy did not meaningfully change exposure.” The absence of a first stage is especially problematic given partial geographic coverage, uncertain compliance, and long lags to mortality.

## 4. **Suggestions**

The paper asks a worthwhile question, and I think there is a publishable project here, but it likely needs to be re-centered around a design that better matches the institutional setting and the expected treatment margin.

**1. Return to the county-level design that motivated the project.**  
This is the single most important recommendation. The natural specification is at the county-year level:
\[
Y_{cst}=\beta(\text{RRNC}_{cst}\times \text{GRP}_c)+\lambda_c+\delta_{st}+\varepsilon_{cst},
\]
where \(\lambda_c\) are county fixed effects and \(\delta_{st}\) are state-year fixed effects. This design has several advantages:

- It absorbs all statewide shocks in a given year: smoking policy, Medicaid expansion, oncology treatment trends, macroeconomic conditions, code enforcement changes, etc.
- It lets identification come from whether counties with higher underlying radon potential differentially improve after a statewide policy.
- It handles the fact that policy bite should be stronger in some counties than others.

If county-level lung cancer mortality is difficult because of suppression or access constraints, you should be transparent that the preferred design is not currently feasible and reframe the paper as a descriptive/power paper rather than a causal evaluation. But given the manifest, the stronger design appears feasible and should be pursued.

**2. Use the correct outcome: lung cancer, not all cancer.**  
The current outcome choice is too blunt. Radon is not expected to move total cancer mortality in a detectable way over this horizon. If you cannot obtain county-level lung cancer mortality, consider alternatives:

- state-level lung cancer mortality from a different source;
- SEER incidence or mortality where available;
- age-sex-race-specific lung cancer outcomes if that helps with power;
- non-smoker lung cancer, if any proxy can be constructed, though I suspect that is difficult.

Even if coverage is incomplete, a more targeted outcome would be much more informative than all-cancer mortality. A smaller but valid sample is preferable to a large sample with overwhelming outcome mismeasurement.

**3. Implement the policy geography correctly.**  
The paper notes that some states adopted RRNC only in Zone 1 counties. This matters. Treatment should be coded at the county level where applicable. If you remain at the state level, at least construct treatment intensity as the population share or housing-stock share subject to the code, not a simple post indicator. Washington and Michigan should not be treated as full-state adoptions.

More generally, I would encourage a treatment variable closer to **effective exposure reduction**, for example:
- share of state/county population in covered areas,
- share of housing permits in covered areas,
- interaction of code coverage with geology and new-construction intensity.

That would move the empirical object closer to the true treatment margin.

**4. Add a first-stage section and make it central.**  
Because mortality effects are long-run and likely small, the most policy-relevant near-term contribution may be to show whether RRNC codes changed proximate outcomes. I would strongly encourage assembling at least one of the following:

- indoor radon test results or testing rates;
- home radon mitigation installations;
- new residential permitting or housing starts;
- adoption/compliance proxies from code enforcement or builder surveys;
- listing-level or appraisal data indicating radon systems in homes;
- age-of-housing interactions using ACS year-built shares.

A particularly useful design would estimate whether RRNC adoption reduced radon readings in newly built homes or increased the prevalence of radon-resistant features in new construction. Then, using epidemiological dose-response estimates, you could present an evidence-based long-run projection. That would be much more compelling than inferring mechanism from a null mortality effect alone.

**5. Address smoking and other lung-cancer confounders more directly.**  
Even with state-year or county-year fixed effects, smoking remains the first-order confounder for any lung-cancer analysis. I would recommend incorporating:
- state-year smoking prevalence from BRFSS,
- cigarette taxes and clean indoor air laws,
- Medicaid expansion and insurance coverage,
- demographic controls if working at county level,
- perhaps interactions with baseline smoking intensity.

In the preferred county design with state-year FE, many statewide policy confounders are absorbed automatically, but county-level differential smoking trends could still matter. At minimum, I would show that high- and low-GRP counties within adopting states had similar pre-trends in smoking-related outcomes before adoption.

**6. Reconsider the interpretation of “parallel trends.”**  
The paper currently treats a visually flat event study as fairly strong support for identification. With only a small number of treated states, substantial attenuation, and noisy state-level outcomes, pre-trend tests have low power. I suggest a more cautious tone. Also, in the county-level version, event studies should be shown separately by geology bins and perhaps weighted by baseline population or housing permits.

Relatedly, I would avoid phrases like “credible null” or “well-powered null.” Your own power discussion shows the opposite for realistic effects. The paper can still make a useful contribution by showing that **short-run mortality effects are not detectable in currently available aggregate data**, which is a different and more defensible claim.

**7. Improve the geology measure.**  
The state-level “share of counties with GRP ≥ 2” is a coarse proxy. It also gives equal weight to tiny and huge counties. Better options include:
- population-weighted GRP share,
- housing-stock-weighted GRP share,
- county mean radon potential based on area overlap rather than centroid assignment,
- continuous county radon measures where possible,
- interaction with EPA radon zones as a validation exercise.

Also, because the USGS GRP classification partly incorporates indoor radon measurements and building characteristics, you should discuss whether this creates any conceptual circularity. It does not destroy exogeneity, but it means the measure is not purely geological. A robustness check using a more geologic-only proxy, if available, would help.

**8. Align the timing more carefully with expected dose accumulation.**  
The paper’s interpretation emphasizes latency and stock turnover, which is sensible. But then the empirical model should reflect that. I would suggest:
- estimating distributed-lag/event-time effects with long bins,
- interacting treatment with years-since-adoption and pre-policy construction intensity,
- constructing a predicted treated housing stock share over time using permits or housing starts,
- estimating effects on cohorts more likely to reside in newer housing.

A simple post dummy is unlikely to map well to biological or exposure timing. If new homes are the only treated units, treatment intensity should rise gradually after adoption, not jump discretely.

**9. Make better use of heterogeneity that should matter.**  
The mechanism suggests stronger effects in:
- counties with high geology-driven radon risk,
- places with substantial new construction,
- single-family detached housing markets,
- areas with basements/slab types vulnerable to radon entry,
- places with greater code enforcement capacity.

These are not just nice additions; they are central to whether RRNC codes can plausibly affect population outcomes in the sample window. In particular, geology × policy × new-construction intensity seems highly relevant.

**10. Revisit the placebo interpretation.**  
The placebo table does not support as strong a claim as the text makes. Some coefficients are statistically significant, including diabetes and stroke. Even if these are likely false positives, the text should not say “none” are significant. More importantly, placebo outcomes are less probative than design-based controls here. If statewide health trends differ across adopters and non-adopters, placebo outcomes may move for many reasons unrelated to radon. I would downweight this section or present randomization-inference-adjusted multiple-testing results.

**11. Be more careful in describing external validity and treatment selection.**  
The paper usefully notes that adopters are different from non-adopters. I would go further and show this formally:
- baseline radon risk,
- political party control,
- income,
- urbanization,
- smoking prevalence,
- baseline lung cancer rates,
- code stringency or IRC adoption patterns.

A table or figure on predictors of adoption would be useful. If adoption is strongly predicted by radon risk and governance capacity, that does not invalidate the study, but it does underscore why within-state county variation is preferable to across-state comparisons.

**12. Consider reframing the paper if better outcome data remain unavailable.**  
If access constraints prevent a convincing county-level lung-cancer design, there is still a potentially useful paper, but it is a different one. For example:

- a paper on why aggregate mortality is the wrong margin for evaluating RRNC in the short run;
- a first-stage paper on code adoption, compliance, and radon exposure;
- a projection paper combining quasi-experimental code effects on radon/testing/building practices with epidemiological dose-response estimates.

That version could still make a meaningful contribution by clarifying the time horizon and data requirements for evaluating prevention policies aimed at long-latency disease.

Overall, the paper is well written, the topic is important, and the discussion of latency and stock turnover is thoughtful. But the current empirical implementation is too far from the most credible design and too weakly aligned with the policy mechanism. If the authors can move toward a county-level, lung-cancer-specific, mechanism-rich analysis, the project would be substantially stronger.
